FDA sends draft interim access policy for peptide compounding to White House review

The White House Office of Information and Regulatory Affairs listing of pending Executive Order 12866 reviews shows that on October 14, 2026 the Department of Health and Human Services and FDA submitted a document titled "Interim Access Policy for Compounding Using Certain Peptides" for review. The listing, RIN 0910-ZD94, describes the stage as a notice, records no legal deadline, and does not mark the policy as economically significant. A submission opens White House review; it does not publish the policy text, and it does not by itself change any regulation or any pharmacy's legal obligations.

Inside Health Policy reported on October 15 that the interim access policy could create a temporary pathway for state-licensed pharmacies to compound certain peptides that are not currently eligible for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. The draft text is not public, and the regulatory listing does not identify which peptides the policy would cover, what conditions would apply, or how long any temporary pathway would last.

The submission follows a July 23-24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, which discussed seven nominated bulk drug substances for the section 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, emideltide (delta sleep-inducing peptide), Semax, and Epitalon. FDA's meeting page lists the uses the agency evaluated for each substance and identifies the public docket, FDA-2025-N-6895. ABC News reported that the committee voted narrowly to recommend adding six of the seven - BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax - and rejected emideltide, whose evidence FDA described as especially weak. Advisory committee votes are recommendations only; FDA is not bound by them.

ABC News also reported that FDA staff scientists had opposed adding every one of the peptides, citing a lack of solid clinical trial data, inconsistent formulations from batch to batch, and the risk of harmful immune reactions, while committee members who voted yes described regulated compounding as a way to steer consumers away from an unregulated online market. The same report noted that six of the eight recently appointed committee members run clinics that offer peptides. These characterizations are the news outlet's reporting, not FDA findings.

Doctors for America, a physician advocacy group, issued a statement on October 16 urging the White House to reject the interim access policy. The Executive Order 12866 review process has no legal deadline for this item, and review length varies; after review, FDA could publish the policy, revise it, or withdraw it. Separate formal rulemaking on which bulk substances may join the 503A list continues on its own track.

Limits: nothing in the listing or the reporting establishes that any peptide is safe, effective, or legal to compound or prescribe. The substances discussed are not FDA-approved drugs, and an advisory vote or a pending review is not evidence of benefit. This brief is a regulatory-status report, not treatment guidance, dosing information, or a source for obtaining any peptide.